Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate Xanamem (emestedastat) in patients with biomarker-positive Alzheimer’s disease (AD). The company is on track to report a pre-planned interim efficacy (

07 Jul 2025
Actinogen Medical:XanaMIA study enrols 100th patient

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Actinogen Medical:XanaMIA study enrols 100th patient
Actinogen Medical Limited (ACW:ASX) | 0 0 -9.4% | Mkt Cap: 35.9m
- Published:
07 Jul 2025 -
Author:
Jyoti Prakash, CFA | Pooya Hemami, OD MBA, CFA -
Pages:
10 -
Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate Xanamem (emestedastat) in patients with biomarker-positive Alzheimer’s disease (AD). The company is on track to report a pre-planned interim efficacy (